Stockreport

Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF NTLA's ATTR program is on clinical hold, with no clear timeline for regulatory resolution and persistent platform-level liver risk. Lonvo-z, the HAE program, faces a [Read more]